EpiAxis Therapeutics to present at Biotech Showcase 2023
EpiAxis Therapeutics, a leading LSD1 company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, is presenting at Biotech Showcase™ 2023. EpiAxis CEO Dr Jeremy Chrisp will discuss the company's focus on developing...
EpiAxis enters agreement with Seattle Children’s Research Institute
EpiAxis Therapeutics has signed a material transfer agreement (MTA) with Seattle Children’s Research Institute that will help researchers study a new approach to treating paediatric brain cancer. As part of the agreement, EpiAxis Therapeutics will supply its lead...
EpiAxis joins Tech Tuesday panel discussion
EpiAxis Therapeutics CEO Dr Jeremy Chrisp this week joined Tech Tuesdays, a Canadian Securities Exchange virtual showcase that features in-depth discussions with companies shaking up the technology industry. The episode - Precision Medicine in Cancer Treatment - was a...
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics